Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells

Background This study aimed to investigate the mechanism of CHEK2 gene dysfunction in drug resistance of triple negative breast cancer (TNBC) cells. Material/Methods To perform our study, a stable CHEK2 wild type (CHEK2 WT) or CHEK2 Y390C mutation (CHEK2 Y390C) expressed MDA-MB-231 cell line was established. MTT assay, cell apoptosis assay and cell cycle assay were carried out to analyze the cell viability, apoptosis, and cell cycle respectively. Western blotting and qRT-PCR were applied for related protein and gene expression detection. Results We found that the IC50 value of DDP (Cisplatin) to CHEK2 Y390C expressed MDA-MB-231 cells was significantly higher than that of the CHEK2 WT expressed cells and the control cells. After treatment with DDP for 48 h, cells expressing CHEK2 WT showed lower cell viability than that of the CHEK2 Y390C expressed cells and the control cells; compared with the CHEK2 Y390C expressed cells and the control cells, cells expressing CHEK2 WT showed significant G1/S arrest. Meanwhile, we found that compared with the CHEK2 Y390C expressed cells and the control cells, cell apoptosis was significantly increased in CHEK2 WT expressed cells. Moreover, our results suggested that cells expressing CHEK2 WT showed higher level of p-CDC25A, p-p53, p21, Bax, PUMA, and Noxa than that of the CHEK2 Y390C expressed cells and the control cells. Conclusions Our findings indicated that CHEK2 Y390C mutation induced the drug resistance of TNBC cells to chemotherapeutic drugs through administrating cell apoptosis and cell cycle arrest via regulating p53 activation and CHEK2-p53 apoptosis pathway.

[1]  Zhi-rui Zhou,et al.  Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[2]  M. Brackstone,et al.  G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance , 2017, Scientific Reports.

[3]  N. Saki,et al.  An association study between CHEK2 gene mutations and susceptibility to breast cancer , 2017, Comparative Clinical Pathology.

[4]  Minna K. Lee,et al.  CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer , 2017, Oncotarget.

[5]  C. Deng,et al.  WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance , 2017, Scientific Reports.

[6]  Samayita Das.  Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance. , 2016, Medical hypotheses.

[7]  K. Mnich,et al.  Nerve growth factor (NGF)-mediated regulation of p75(NTR) expression contributes to chemotherapeutic resistance in triple negative breast cancer cells. , 2016, Biochemical and biophysical research communications.

[8]  S. Bojesen,et al.  Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Hainaut,et al.  Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil , 2016, Genetics and molecular biology.

[10]  M. Hemann,et al.  A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency , 2015, EMBO molecular medicine.

[11]  H. Jiang,et al.  A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk , 2015, Oncogene.

[12]  J. Benítez,et al.  About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants , 2014, International journal of cancer.

[13]  A. Rehman,et al.  Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin , 2014, Molecular Biology Reports.

[14]  Ning Wang,et al.  XRCC3 and RAD51 Expression Are Associated with Clinical Factors in Breast Cancer , 2013, PloS one.

[15]  H. Akkız,et al.  CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population. , 2012, Cancer epidemiology.

[16]  P. Lønning,et al.  Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer , 2012, Breast Cancer Research.

[17]  P. Souček,et al.  CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer. , 2010, Cancer epidemiology.

[18]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[19]  Steinar Lundgren,et al.  CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer , 2008, PloS one.

[20]  Tom Walsh,et al.  Ten genes for inherited breast cancer. , 2007, Cancer cell.

[21]  M. Lacroix,et al.  The “portrait” of hereditary breast cancer , 2005, Breast Cancer Research and Treatment.

[22]  J. Bartek,et al.  Chk2 kinase — a busy messenger , 2001, Nature Reviews Molecular Cell Biology.

[23]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[24]  D. Meek,et al.  Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. , 2001, The Biochemical journal.

[25]  Penny A. Jeggo,et al.  The role of double-strand break repair — insights from human genetics , 2006, Nature Reviews Genetics.